Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia

Next Previous
Trial Profile

Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
  • Indications Hyperlipidaemia; Hypertension
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical

Most Recent Events

  • 11 Oct 2016 Primary endpoint has been met. (Change from baseline to 8 week in Blood Pressure. [ Time Frame: baseline and 8 week ] [ Designated as safety issue: No ]), according to results published in the Clinical Therapeutics.
  • 11 Oct 2016 Primary endpoint has been met. (Percent change from baseline to 8 week in LDL-Cholesterol [ Time Frame: baseline and 8 week ] [ Designated as safety issue: No ]), according to results published in the Clinical Therapeutics.
  • 11 Oct 2016 Results published in the Clinical Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top